Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the fourth quarter and year ended December 31, 2010.

"As we begin 2011, we believe Anadys is well-positioned to create value in the evolving HCV landscape," said Steve Worland, Ph.D., President and CEO of Anadys.  "Last year, we demonstrated important safety and efficacy parameters for ANA598 in combination with current treatment over twelve weeks. We look to extend these results with the recently initiated Phase IIb study which should set the stage for Phase III development.  Additionally, we plan to advance ANA773, our oral interferon inducer being developed as a pan-genotypic agent for HCV."

Development Program HighlightsANA598

  • Phase IIb Study Underway Dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin (SOC) for the treatment of chronic hepatitis C (HCV).  ANA598, the Company's direct-acting antiviral (DAA), is being tested in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.
  • 2011 Milestones – The Company expects to receive Week 8 antiviral response data for treatment-naive patients by the end of the second quarter of 2011, Week 12 antiviral response data for treatment-experienced patients in the third quarter of 2011 and Week 24 antiviral response data for both groups in the fourth quarter of 2011. 
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/25/2014)... The report “Service Quality ... by Product Type & Provider Type - ... defines and segments the market with an ... , Browse 152 market data tables, 19 ... TOC on “Service Quality Management (SQM) and ...
    (Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
    (Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech ... patient care in critical areas, announced the closing of ... stock, and warrants to purchase up to an aggregate ... of $4.00 per share and $.01 per warrant.  The ... are exercisable immediately, and expire 5 years from the ...
    (Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
    Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
    ... CALGARY, May 22 /PRNewswire-FirstCall/ - Oncolytics Biotech ... has,successfully transferred cGMP production for REOLYSIN(R) at ... Division of Sigma-Aldrich Corporation.,This follows the successful ... announced,by the Company last year., Yields ...
    ... AMSTERDAM, The Netherlands, May 22 Amsterdam,Molecular ... field of human gene,therapy, today announced that ... in Rome, Italy, to their advanced small ... of Duchenne,muscular dystrophy (DMD). The combination with ...
    ... SOUTH SAN FRANCISCO, Calif., May 21 Exelixis,Inc. (Nasdaq: ... and,analyst briefing in conjunction with the 44th Annual Meeting of ... 8:00 p.m. CT,on Monday, June 2, 2008., Participants:, ... Officer -- Michael M. Morrissey, PhD, President of Research ...
    Cached Biology Technology:Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 2AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4
    (Date:12/24/2014)... 2014  Since its launch in December 2014, the ... to eliminate the pain of trying to remember their ... their own biometrics fused to their smartphones. To assist ... Hoyos Labs , the company that created 1U ... is offering the app for free. 1U ...
    (Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... consultant, Apollo Robbins for the 2015 International ... Apollo Robbins will be at ... 2015, demonstrating some of his famous theft techniques to ...
    (Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
    Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
    ... world,s subspecies of tigers are now extinct. A new study ... a result of human activities, particularly the conversion of natural ... The study, conducted by Virginia Tech and World Wildlife ... investigate the use of different land cover types not ...
    ... February 29, 2012 A revealing study published in ... epilepsy is not faring well in social media. Kate McNeil ... from Twitter to provide a snapshot of how epilepsy is ... platform launched in 2006, allows its users to communicate through ...
    ... Wednesday, Feb. 29, 2012, Cleveland: Cleveland Clinic Children,s Hospital ... can be used to help identify children who are ... is designed to confirm the predictive value of established ... that have been completed. Thomas Frazier, Ph.D., of ...
    Cached Biology News:Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 2Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 3Is Twitter reinforcing negative perceptions of epilepsy? 2Cleveland Clinic Children's Hospital launches study to genetically test for autism 2
    ... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
    ... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
    ... digital scanner serves as the spot-picking platform. ... standard rack positions on the tray, leaving ... plates on the remaining two racks.,The software ... by mouse-click on the scanned gel image. ...
    ... for whole-blood clinical diagnostic work in hospitals ... this analyzer makes precise glucose measurements of ... lactate measurements of whole blood, plasma, or ... allows you to have glucose results expressed ...
    Biology Products: